Abstract:Abstract Background Studies have reported conflicting findings regarding the effect of timing of biologics initiation on disease course, often affected by selection and referral biases. In this nationwide cohort study we aimed to explore whether early initiation of biologics is associated with better disease outcomes in CD and UC. Methods Data of patients diagnosed with IBD in the epi-IIRN cohort from 2005 to 2020 were retrieved from 4 Israeli Health-Maintenance-Organizations covering 98% of the population.The primary analysis was time to steroid-dependency and IBD-related surgery. To control for confounding by indication in which the severity of disease could account both for the timing of biologics and risk of disease outcomes,we compared treatment strategies using the cloning,censoring and weighting method to emulate a target trial. Inverse probability of treatment weights were fitted per patient to adjust by weighting for time varying confounding and selection bias.Survival probabilities(POS) were estimated and compared at 10 years post diagnosis for each strategy through weighted non-parametric Kaplan-Meier estimators. The 95%CIs for survival probabilities were calculated using non-parametric bootstrap with 500 replicates. Results Of the 34,375 patients diagnosed with IBD, 7,452(39%) CD patients and 2,235(15%) UC patients received biologics and included in the analysis. In total,1,139 CD and 206 UC patients received biologics during the first three months after diagnosis,2,108 CD and 450 UC during the 3-12 month period,1,161 CD and 396 UC during 1-2 year period,and 719 CD and 271 UC during 2-3 years post diagnosis. Patients who initiated biologics after 3 years post diagnosis were excluded as they were not considered early biologics initiation.In CD,at 10 years post diagnosis there was a significant but modest decrease in IBD-related surgeries when initiating biologics prior to 3 months compared to the other periods (POS:0-3 months 0.75[CI 0.71- 0.79] vs 2-3 year 0.7[CI 0.66-0.73] ;p<0.05).The same observation with a larger effect, was apparent for steroid-dependency (POS:0-3 months 0.78[CI 0.75-0.82] vs 2-3 year 0.69[CI 0.66-0.71]; p<0.001)(Fig 1). In UC, no significant differences in colectomy rate at 10 years was observed between the treatment periods (POS:0-3 months 0.92[CI 0.87-0.97] vs. 2-3 years 0.94[CI 0.91-0.98];p=0.42). On the other hand, a significant decrease was apparent for steroid-dependency (POS:0-3 months 0.78[CI 0.75-0.82] vs 2-3 year 0.69[CI 0.66-0.71];p<0.001)(Fig 2). Conclusion Our study showed a slight advantage to earlier initiation of biologics,as reflected by longer time to IBD-related surgery and steroid-dependency in CD.In UC, the effect of early biologics was minor and was only apparent for steroid dependency in UC.

Efficacy of Biologic Drugs in Short-Duration Versus Long-Duration Inflammatory Bowel Disease: A Systematic Review and an Individual-Patient Data Meta-Analysis of Randomized Controlled Trials

EFFICACY OF BIOLOGIC DRUGS IN SHORT-DURATION VERSUS LONG-DURATION INFLAMMATORY BOWEL DISEASE: A SYSTEMATIC REVIEW AND INDVIDUAL-PATIENT-DATA METANALYSIS OF RANDOMIZED CONTROLLED TRIALS

Efficacy of Biological Drugs in Short-Duration Versus Long-Duration Inflammatory Bowel Disease: a Protocol for a Systematic Review and an Individual-Patient Level Meta-Analysis of Randomised Controlled Trials

Anti‐TNF and Immunosuppressive Combination Therapy is Preferential to Inducing Clinical Remission in Patients with Active Inflammatory Bowel Disease: A Systemic Review and Meta‐analysis

Biologic Therapy for Crohn's Disease over the Last 3 Decades.

The Efficacy and Safety of Biological and Immunosuppressive Combination Therapy Are Equal to Biological Monotherapy for Inflammatory Bowel Disease: A Systemic Review and Meta-Analysis

OP12 Does early initiation of biologics change the natural history of IBD? a nationwide study from the epi-IIRN

Efficacy of Biological Therapies in Inflammatory Bowel Disease: Systematic Review and Meta-Analysis

P879 Comparative Efficacy of Biologics and Small Molecule Therapies for the Induction and Maintenance of Endoscopic and Histological Remission in Ulcerative Colitis: A Systematic Review and Network Meta-analysis

Network meta‐analysis: Comparative onset of early effect of biologics and small molecules in moderately to severely active luminal Crohn's disease

Systematic review with meta-analysis of the effectiveness of subcutaneous biologics versus intravenous biologics in inflammatory bowel diseases

Sa1796 Diet-Induced Secretion of Incretins is Regulated by Nutrients in the Stomach

Early Initiation of Biologics and Disease Outcomes in Children and Adults With Inflammatory Bowel Diseases: Results From the Epidemiology Group of the Nationwide Israeli Inflammatory Bowel Disease Research Nucleus Cohort

NETWORK META-ANALYSIS TO EVALUATE THE COMPARATIVE EFFICACY OF BIOLOGICS FOR MAINTENANCE TREATMENT OF ADULT PATIENTS WITH CROHN’S DISEASE

P935 Remission rates of biologics and small molecules in extension studies of moderate to severe Ulcerative Colitis; A systematic review and Network Meta-analysis

Shorter Crohn's Disease Duration Is Associated With Better Clinical and Endoscopic Outcomes With Risankizumab in Phase 3 Studies

P647 Effectiveness of combined treatment with two biologics or advanced molecules in inflammatory bowel disease

Real-World Treatment Patterns and Physician Preferences for Biologics in Moderate-to-Severe Inflammatory Bowel Disease: Retrospective Chart Review in Europe

Optimizing Biologic Treatment in IBD: Objective Measures, but When, How and How Often?

Evaluation of adverse clinical outcomes in patients with inflammatory bowel disease receiving different sequences of first- and second-line biologic treatments: findings from ROTARY

The Efficacy of Currently Licensed Biologics for Treatment of Ulcerative Colitis: A Literature Review